KR20150103747A - 2-((1r,4r)-4-(4-(5-(벤족사졸-2-일아미노)피리딘-2-일)페닐)시클로헥실)아세트산의 메글루민 염 형태 및 dgat1 억제제로서의 그의 용도 - Google Patents

2-((1r,4r)-4-(4-(5-(벤족사졸-2-일아미노)피리딘-2-일)페닐)시클로헥실)아세트산의 메글루민 염 형태 및 dgat1 억제제로서의 그의 용도 Download PDF

Info

Publication number
KR20150103747A
KR20150103747A KR1020157021323A KR20157021323A KR20150103747A KR 20150103747 A KR20150103747 A KR 20150103747A KR 1020157021323 A KR1020157021323 A KR 1020157021323A KR 20157021323 A KR20157021323 A KR 20157021323A KR 20150103747 A KR20150103747 A KR 20150103747A
Authority
KR
South Korea
Prior art keywords
rti
cyclohexyl
phenyl
pyridin
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157021323A
Other languages
English (en)
Korean (ko)
Inventor
크리스티나 카파치-다니엘
마릴린 델라크루즈
바오칭 공
아카시 자인
얀송 루
리준 장
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150103747A publication Critical patent/KR20150103747A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157021323A 2013-01-11 2014-01-10 2-((1r,4r)-4-(4-(5-(벤족사졸-2-일아미노)피리딘-2-일)페닐)시클로헥실)아세트산의 메글루민 염 형태 및 dgat1 억제제로서의 그의 용도 Ceased KR20150103747A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751443P 2013-01-11 2013-01-11
US61/751,443 2013-01-11
PCT/US2014/011005 WO2014110344A1 (en) 2013-01-11 2014-01-10 Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors

Publications (1)

Publication Number Publication Date
KR20150103747A true KR20150103747A (ko) 2015-09-11

Family

ID=50001335

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021323A Ceased KR20150103747A (ko) 2013-01-11 2014-01-10 2-((1r,4r)-4-(4-(5-(벤족사졸-2-일아미노)피리딘-2-일)페닐)시클로헥실)아세트산의 메글루민 염 형태 및 dgat1 억제제로서의 그의 용도

Country Status (16)

Country Link
US (2) US8987459B2 (enExample)
EP (1) EP2943488B1 (enExample)
JP (1) JP6302937B2 (enExample)
KR (1) KR20150103747A (enExample)
CN (1) CN104995188B (enExample)
AR (1) AR101523A1 (enExample)
AU (1) AU2014205276B2 (enExample)
BR (1) BR112015016370A2 (enExample)
CA (1) CA2896861A1 (enExample)
EA (1) EA027688B1 (enExample)
ES (1) ES2675398T3 (enExample)
MX (1) MX2015008978A (enExample)
PL (1) PL2943488T3 (enExample)
PT (1) PT2943488T (enExample)
TR (1) TR201808198T4 (enExample)
WO (1) WO2014110344A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995188B (zh) * 2013-01-11 2018-09-14 诺华股份有限公司 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
US10822346B2 (en) * 2018-04-17 2020-11-03 Cardurion Pharmaceuticals, Llc Meglumine salts of thienopyrimidines
MX2023005447A (es) * 2020-11-10 2023-09-25 Unity Biotechnology Inc Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CN104995188B (zh) * 2013-01-11 2018-09-14 诺华股份有限公司 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途

Also Published As

Publication number Publication date
CA2896861A1 (en) 2014-07-17
EA201591300A1 (ru) 2015-11-30
CN104995188B (zh) 2018-09-14
AU2014205276A1 (en) 2015-07-16
EP2943488A1 (en) 2015-11-18
MX2015008978A (es) 2015-09-29
WO2014110344A1 (en) 2014-07-17
AU2014205276B2 (en) 2016-10-20
CN104995188A (zh) 2015-10-21
ES2675398T3 (es) 2018-07-11
PL2943488T3 (pl) 2018-09-28
US8987459B2 (en) 2015-03-24
JP6302937B2 (ja) 2018-03-28
EA027688B1 (ru) 2017-08-31
PT2943488T (pt) 2018-06-12
EP2943488B1 (en) 2018-03-28
BR112015016370A2 (pt) 2017-07-11
JP2016505017A (ja) 2016-02-18
US20150166522A1 (en) 2015-06-18
US9242971B2 (en) 2016-01-26
AR101523A1 (es) 2016-12-28
TR201808198T4 (tr) 2018-07-23
US20140200246A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
EP2852590B1 (en) Cyclic bridgehead ether dgat1 inhibitors
ES2649564T3 (es) Inhibidores de DGAT
EA017260B1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
US20140343102A1 (en) Crystalline forms of the sodium salt of (4--cyclohexyl)-acetic acid
WO2024063143A1 (ja) Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物
US9242971B2 (en) Compounds for the treatment of conditions associated with DGAT1 activity
ES2350600T3 (es) Modulador de ppar que contiene oxazol y tiazol.
JP7653399B2 (ja) オキサジアゾール誘導体を含有する医薬組成物
HK1183485B (en) New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid
HK1183485A (en) New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150806

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190104

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200421

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200727

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200421

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I